Although there have been advances in treatment, the incidence, morbidity, and mortality associated with acute coronary syndrome (ACS) remain significant. Therapy for ACS utilizes a combination of surgical interventions (including percutaneous coronary interventions [PCI]) and pharmacotherapy, with antiplatelet agents playing an essential role. There may be significant risks with these interventions, during the procedure itself and in the months and years following. Ischemic events can continue to occur, despite the use of either standard antiplatelet therapy or variations in dosages and combinations of agents.
After taking part in this educational activity, participants should be better able to:
- Discuss current approaches to the management of patients with acute coronary syndromes (ACS), particularly those undergoing percutaneous coronary intervention (PCI)
- Review the current guidelines of the American College of Cardiology/ American Heart Association/Society for Cardiovascular Angiography and Interventions regarding use of dual antiplatelet therapy to prevent myocardial infarction (MI) and death in patients following PCI
- Describe the concept of thienopyridine “resistance,” and recognize its potential implications for secondary prevention in patients post-ACS
- Evaluate emerging options for antiplatelet therapy post-ACS, including new thienopyridines, non-thienopyridines, and other agents, taking into consideration their safety, efficacy, and mechanisms of action in patients with ACS.
AMA PRA Category 1 Credit(s)TM
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Albert Einstein Designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™.
James A. de Lemos, MD
Assistant Professor, Internal Medicine – Cardiology
Southwestern Medical School
UT Southwestern Medical Center
Yerem Yeghiazarians, MD
Director, UCSF Cardiac Stem Cell Translational Development Program
Co-Director, Adult Cardiac Catheterization Laboratory
Director, Peripheral Interventional Cardiology Program
UCSF Medical Center
San Francisco, CA
Deepak L. Bhatt, MD, MPH
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular Program
Brigham and Women’s Hospital and the VA Boston Healthcare System
Senior Investigator, TIMI Study Group
Harvard Medical School
Roy Blank, MD
Presbyterian Novant Medical Group
Medical Director and Associate Professor, Physician Assistant Program
CME COURSE REVIEWER
E. Scott Monrad, MD
Professor of Clinical Medicine
Albert Einstein College of Medicine
Director, Cardiac Catheterization Laboratory
Einstein Division, Montefiore Medical Center
It is the policy of Albert Einstein College of Medicine to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. In accordance with ACCME policies and standards, all faculty participating in any sponsored activity are expected to disclose to the audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing educational activities in which they participate. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other entities. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is required by the ACCME that each speaker disclose to the audience any discussion of unlabeled use of a commercial product or device or an investigational use not yet approved for any purpose.
James A. de Lemos, MD, has received speakers’ honoraria from Merck/Schering, Pfizer Inc, and sanofi-aventis–Bristol-Myers Squibb partnership; consulting fees from Biosite, Roche, and Pfizer Inc; and research grants from Biosite.
Deepak L. Bhatt, MD, MPH, has received grants/research support from Bristol-Myers Squibb Company; Eisai Inc.; Ethicon, Inc.; Heartscape Technologies, Inc.; sanofi-aventis; and The Medicines Company.
Yerem Yeghiazarians, MD, is a member of the speakers’ bureaus for Pfizer Inc, sanofi aventis—Bristol-Myers Squibb partnership, and Daiichi Sankyo, Inc.
E. Scott Monrad, MD, has no relevant financial relationships to disclose.
Supported by an educational grant from Daiichi Sankyo and Lilly USA, LLC.
Sponsored by Albert Einstein College of Medicine of Yeshiva University.
To obtain credit, a score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.